Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24390485 | 1.00 | ANPEP (0.45) | ANPEPENPEPALDH1A1LMNASLC15A2 | |
| SCHEMBL22994945 | 0.88 | ANPEP (0.56) | ANPEPENPEPALDH1A1LMNASLC15A2 | |
| SCHEMBL26864412 | 0.82 | ANPEP (0.45) | ANPEPENPEPALDH1A1LMNASLC15A2 | |
| SCHEMBL16710258 | 0.82 | ANPEP (0.67) | ANPEPENPEPKDM4E | |
| SCHEMBL16768817 | 0.80 | ANPEP (0.70) | ANPEPENPEPALDH1A1LMNASLC15A2 | |
| SCHEMBL25943327 | 0.80 | ANPEP (0.70) | ANPEPENPEPALDH1A1LMNASLC15A2 | |
| SCHEMBL16710256 | 0.80 | ANPEP (0.44) | ANPEPENPEP | |
| SCHEMBL20353370 | 0.78 | KISS1R (0.43) | ANPEPENPEPALDH1A1TDP1 | |
| SCHEMBL2758953 | 0.78 | TSHR (0.48) | ANPEPENPEPALDH1A1LMNAKDM4E | |
| SCHEMBL8861959 | 0.78 | TSHR (0.48) | ANPEPENPEPALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174301-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20200140505-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140505-A1 | PEPTIDE COMPOUND | GIPR, GLP1R, GRPR | ANPEP 109/4885ENPEP 244/4885ALDH1A1 4573/4885 |
| US-11174301-B2 | Peptide compound | GIPR, GLP1R, GRPR | ANPEP 109/4885ENPEP 244/4885ALDH1A1 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.